BRPI1014760B8 - preparação compreendendo insulina, nicotinamida e arginina - Google Patents

preparação compreendendo insulina, nicotinamida e arginina

Info

Publication number
BRPI1014760B8
BRPI1014760B8 BRPI1014760A BRPI1014760A BRPI1014760B8 BR PI1014760 B8 BRPI1014760 B8 BR PI1014760B8 BR PI1014760 A BRPI1014760 A BR PI1014760A BR PI1014760 A BRPI1014760 A BR PI1014760A BR PI1014760 B8 BRPI1014760 B8 BR PI1014760B8
Authority
BR
Brazil
Prior art keywords
insulin
nicotinamide
preparation
arginine
amino acid
Prior art date
Application number
BRPI1014760A
Other languages
English (en)
Inventor
Birk Olsen Helle
Naver Helle
Sturis Jeppe
Schlein Morten
Havelund Svend
Ludvigsen Svend
Ribel Ulla
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41351568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1014760(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of BRPI1014760A2 publication Critical patent/BRPI1014760A2/pt
Publication of BRPI1014760A8 publication Critical patent/BRPI1014760A8/pt
Publication of BRPI1014760B1 publication Critical patent/BRPI1014760B1/pt
Publication of BRPI1014760B8 publication Critical patent/BRPI1014760B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

preparação compreendendo insulina, nicotinamida e um aminoácido. a presente invenção refere-se a preparações de insulina compreendendo um composto de insulina ou uma mistura de dois ou mais compostos de insulina, um composto nicotínico e um aminoácido.
BRPI1014760A 2009-06-26 2010-06-25 preparação compreendendo insulina, nicotinamida e arginina BRPI1014760B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP09163940 2009-06-26
EP09163940.1 2009-06-26
US22216809P 2009-07-01 2009-07-01
US61/222,168 2009-07-01
PCT/EP2010/059069 WO2010149772A1 (en) 2009-06-26 2010-06-25 Preparation comprising insulin, nicotinamide and an amino acid

Publications (4)

Publication Number Publication Date
BRPI1014760A2 BRPI1014760A2 (pt) 2017-07-18
BRPI1014760A8 BRPI1014760A8 (pt) 2018-01-09
BRPI1014760B1 BRPI1014760B1 (pt) 2021-04-13
BRPI1014760B8 true BRPI1014760B8 (pt) 2021-05-25

Family

ID=41351568

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1014760A BRPI1014760B8 (pt) 2009-06-26 2010-06-25 preparação compreendendo insulina, nicotinamida e arginina

Country Status (20)

Country Link
US (4) US8324157B2 (pt)
EP (2) EP2612677B1 (pt)
JP (2) JP5669834B2 (pt)
KR (1) KR101775000B1 (pt)
CN (2) CN104667264B (pt)
AU (1) AU2010264636B2 (pt)
BR (1) BRPI1014760B8 (pt)
CA (1) CA2764423A1 (pt)
DK (2) DK2340033T3 (pt)
ES (2) ES2543705T3 (pt)
HU (2) HUE027239T2 (pt)
IL (1) IL216520A (pt)
MX (1) MX2011012764A (pt)
NO (1) NO2017031I1 (pt)
PL (2) PL2612677T3 (pt)
PT (2) PT2612677E (pt)
RU (1) RU2533217C3 (pt)
TW (1) TWI459962B (pt)
WO (1) WO2010149772A1 (pt)
ZA (1) ZA201108942B (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
FR2943538B1 (fr) 2009-03-27 2011-05-20 Adocia Formulation a action rapide d'insuline recombinante humaine
US9018190B2 (en) 2009-03-27 2015-04-28 Adocia Functionalized oligosaccharides
PT2612677E (pt) * 2009-06-26 2015-09-10 Novo Nordisk As Preparação compreendendo insulina, nicotinamida e arginina
CA2821613A1 (en) * 2010-12-14 2012-06-21 Novo Nordisk A/S Preparation comprising insulin, nicotinamide and an amino acid
US9993529B2 (en) 2011-06-17 2018-06-12 Halozyme, Inc. Stable formulations of a hyaluronan-degrading enzyme
GB201113880D0 (en) * 2011-08-12 2011-09-28 Archimed Llp Novel compositions
US20130231281A1 (en) 2011-11-02 2013-09-05 Adocia Rapid acting insulin formulation comprising an oligosaccharide
WO2013102144A2 (en) 2011-12-30 2013-07-04 Halozyme, Inc. Ph20 polypeptede variants, formulations and uses thereof
WO2013186138A1 (en) * 2012-06-14 2013-12-19 Novo Nordisk A/S Preparation comprising insulin, nicotinamide and arginine
ES2670969T3 (es) 2012-11-13 2018-06-04 Adocia Formulación de acción rápida de insulina que comprende un compuesto aniónico sustituido
MX360420B (es) 2012-12-19 2018-10-31 Wockhardt Ltd Una composicion acuosa estable que comprende insulina humana o un analogo o derivado de la misma.
RU2019128331A (ru) * 2013-02-04 2019-12-16 Санофи Стабилизированные фармацевтические составы аналогов инсулина и/или производные инсулина
TWI641381B (zh) * 2013-02-04 2018-11-21 法商賽諾菲公司 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
TW201534726A (zh) 2013-07-03 2015-09-16 Halozyme Inc 熱穩定ｐｈ２０玻尿酸酶變異體及其用途
CN112957455A (zh) 2014-01-09 2021-06-15 赛诺菲 胰岛素类似物和/或胰岛素衍生物的稳定化药物制剂
US20150273022A1 (en) * 2014-02-10 2015-10-01 Biodel Inc. Stabilized ultra-rapid-acting insulin formulations
EP3113791B1 (en) * 2014-03-07 2018-12-26 Jørgensen, Klavs Holger Novel fast acting insulin preparations
JO3624B1 (ar) * 2014-05-08 2020-08-27 Lilly Co Eli تركيبات إنسولين سريعة المفعول
US9795678B2 (en) 2014-05-14 2017-10-24 Adocia Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound
FR3020947B1 (fr) 2014-05-14 2018-08-31 Adocia Composition aqueuse comprenant au moins une proteine et un agent solubilisant, sa preparation et ses utilisations
TW201630622A (zh) 2014-12-16 2016-09-01 美國禮來大藥廠 速效胰島素組合物
WO2017015760A1 (en) 2015-07-28 2017-02-02 Societe De Commercialisation Des Produits De La Recherche Appliquee Socpra Sciences Sante Et Humaines, S.E.C. A pharmaceutical preparation for improving absorption and postprandial hypoglycemic action of insulin
JO3749B1 (ar) 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
FR3043557B1 (fr) 2015-11-16 2019-05-31 Adocia Composition a action rapide d'insuline comprenant un citrate substitue
GB201607918D0 (en) 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
GB201613895D0 (en) * 2016-08-12 2016-09-28 Arecor Ltd Novel composition
EP3518893A1 (en) 2016-09-29 2019-08-07 Arecor Limited Novel formulations
GB201707187D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
GB201707189D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
GB201707188D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
CA3094237A1 (en) 2018-04-04 2019-10-10 Arecor Limited Medical infusion pump system for the delivery of an insulin compound
WO2019193351A1 (en) 2018-04-04 2019-10-10 Arecor Limited Medical infusion pump system for the delivery of an insulin compound
IL277731B2 (en) 2018-04-04 2024-03-01 Arecor Ltd Medical infusion pump system for the delivery of an insulin compound
FR3083985A1 (fr) 2018-07-23 2020-01-24 Adocia Dispositif pour injecter une solution d'insuline(s)
WO2019243627A1 (fr) 2018-06-23 2019-12-26 Adocia Dispositif pour injecter une solution d'insuline(s)
FR3083984A1 (fr) 2018-07-23 2020-01-24 Adocia Dispositif pour injecter une solution d'insuline(s)
EP3853200B1 (en) 2018-09-18 2024-01-24 Eli Lilly and Company Erbumine salt of treprostinil
GB202004814D0 (en) 2020-04-01 2020-05-13 Arecor Ltd Novel formulations
AR131148A1 (es) 2022-11-26 2025-02-19 Obshchestvo S Ogranichennoy Otvetstvennostyu «Geropharm» Composiciones de insulina de acción rápida (variantes de las mismas)
CN120676958A (zh) 2022-12-04 2025-09-19 吉洛法姆有限责任公司 门冬胰岛素组合物（实施方式）
TW202521158A (zh) * 2023-11-17 2025-06-01 大陸商上海藥明生物技術有限公司 用於高濃度蛋白製劑的降黏穩定製劑

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4205126A (en) * 1978-01-01 1980-05-27 Cartaya Oscar A Serum-free cell culture media
NZ199391A (en) 1981-01-02 1985-12-13 Genentech Inc Chimeric polypeptides comprising a proinsulin sequence,and preparation by recombinant dna technique;production of human insulin
ZA827928B (en) * 1981-10-30 1983-08-31 Novo Industri As Stabilized insulin preparations and process for preparation thereof
DE3313386A1 (de) * 1983-04-13 1984-10-18 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V., 8000 München Verfahren zur herstellung von nicht-brennbaren, thermisch isolierenden formkoerpern aus geblaehtem perlit
DK58285D0 (da) 1984-05-30 1985-02-08 Novo Industri As Peptider samt fremstilling og anvendelse deraf
DK336188D0 (da) 1988-06-20 1988-06-20 Nordisk Gentofte Propeptider
DK105489D0 (da) 1989-03-03 1989-03-03 Novo Nordisk As Polypeptid
CA2070814A1 (en) 1989-12-21 1991-06-22 Klavs H. Jorgensen Insulin preparations containing nicotinic acid or nicotinamide
WO1995016708A1 (en) 1993-12-17 1995-06-22 Novo Nordisk A/S Proinsulin-like compounds
RU2175556C2 (ru) * 1994-03-07 2001-11-10 Инхейл Терапьютик Системз Способы и композиции для легочной доставки инсулина
US6500645B1 (en) 1994-06-17 2002-12-31 Novo Nordisk A/S N-terminally extended proteins expressed in yeast
IL114160A (en) 1994-06-17 2006-12-31 Novo Nordisk As Dna constructs encoding heterologous proteins and processes for the heterologous protein production in yeast
AU3562195A (en) 1994-10-04 1996-04-26 Novo Nordisk A/S Preparations containing aspb28 human insulin and nicotinamide
KR0150565B1 (ko) 1995-02-15 1998-08-17 김정재 유전자 조환에 의한 사람 인슐린 전구체의 제조 및 이를 이용한 인슐린의 제조방법
AU5724996A (en) 1995-05-05 1996-11-21 Eli Lilly And Company Single chain insulin with high bioactivity
US6043092A (en) * 1996-03-18 2000-03-28 University Of Pittsburgh Cell culture media for mammalian cells
US5866538A (en) 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
ZA984697B (en) * 1997-06-13 1999-12-01 Lilly Co Eli Stable insulin formulations.
SI0884053T1 (en) * 1997-06-13 2003-02-28 Eli Lilly And Company Stable insulin formulations
WO2001052937A1 (en) * 2000-01-24 2001-07-26 Medtronic Minimed, Inc. Mixed buffer system for stabilizing polypeptide formulations
US6573237B2 (en) 2001-03-16 2003-06-03 Eli Lilly And Company Protein formulations
DE10114178A1 (de) * 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
CA2452044A1 (en) * 2001-08-28 2003-03-13 Eli Lilly And Company Pre-mixes of glp-1 and basal insulin
US7115563B2 (en) 2002-05-29 2006-10-03 Insignion Holding Limited Composition and its therapeutic use
US20050232974A1 (en) 2004-04-19 2005-10-20 Gore Makarand P System and a method for pharmaceutical dosage preparation using jettable microemulsions
JP2009533471A (ja) 2006-04-12 2009-09-17 バイオデル， インコーポレイテッド 即効型および長時間作用型組合せインスリン製剤
HUE029512T2 (en) 2006-09-22 2017-03-28 Novo Nordisk As Protease Resistant Insulin Analogs
US8518668B2 (en) 2006-09-27 2013-08-27 Novo Nordisk A/S Method for making maturated insulin polypeptides in a fungal cell
WO2008071790A2 (en) 2006-12-15 2008-06-19 Tima Foundation Novel compositions and uses thereof
CN101778862B (zh) * 2007-08-13 2014-12-17 诺沃-诺迪斯克有限公司 快速作用的胰岛素类似物
PT2612677E (pt) * 2009-06-26 2015-09-10 Novo Nordisk As Preparação compreendendo insulina, nicotinamida e arginina

Also Published As

Publication number Publication date
JP2015071608A (ja) 2015-04-16
HUS1700027I1 (hu) 2017-07-28
NO2017031I1 (no) 2017-07-06
HUE027239T2 (en) 2016-10-28
RU2533217C3 (ru) 2020-12-21
PT2340033E (pt) 2014-02-04
RU2012100397A (ru) 2013-08-10
JP6026485B2 (ja) 2016-11-16
CN102470165B (zh) 2014-12-24
JP5669834B2 (ja) 2015-02-18
US8324157B2 (en) 2012-12-04
CN104667264B (zh) 2018-09-07
CN104667264A (zh) 2015-06-03
AU2010264636A1 (en) 2012-01-12
PL2612677T3 (pl) 2015-10-30
AU2010264636B2 (en) 2013-06-27
US20140206610A1 (en) 2014-07-24
KR20120047226A (ko) 2012-05-11
RU2533217C2 (ru) 2014-11-20
EP2340033A1 (en) 2011-07-06
CA2764423A1 (en) 2010-12-29
ES2440289T3 (es) 2014-01-28
KR101775000B1 (ko) 2017-09-04
US20130281364A1 (en) 2013-10-24
EP2612677A1 (en) 2013-07-10
DK2612677T3 (en) 2015-07-27
ES2543705T3 (es) 2015-08-21
BRPI1014760A8 (pt) 2018-01-09
PT2612677E (pt) 2015-09-10
TWI459962B (zh) 2014-11-11
CN102470165A (zh) 2012-05-23
BRPI1014760A2 (pt) 2017-07-18
MX2011012764A (es) 2012-01-20
EP2340033B1 (en) 2013-10-09
DK2340033T3 (da) 2014-01-20
EP2612677B1 (en) 2015-05-06
WO2010149772A1 (en) 2010-12-29
BRPI1014760B1 (pt) 2021-04-13
IL216520A0 (en) 2012-02-29
TW201100093A (en) 2011-01-01
JP2012530768A (ja) 2012-12-06
US20150182595A1 (en) 2015-07-02
PL2340033T3 (pl) 2014-03-31
ZA201108942B (en) 2012-08-29
IL216520A (en) 2017-08-31
US20120135920A1 (en) 2012-05-31

Similar Documents

Publication Publication Date Title
EA201491362A1 (ru) Анестезирующие соединения и способы их применения
JOP20180103A1 (ar) مركب صيدلاني
CY1116987T1 (el) Συμπυκνωμενα ιμιδαζολυλιμιδαζολια ως αντιϊικες ενωσεις
MX2013006174A (es) Preparacion que comprende insulina, nicotinamida y un aminoacido.
EA201400412A1 (ru) ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ
UA109010C2 (en) Morpholino pyrividines and their use in therapy
WO2011156610A3 (en) Quinoline and isoquinoline derivatives as inhibitors of hepatitis c virus
MD20140136A2 (ro) Inhibitori ai virusului hepatic C
GEP20176800B (en) D-amino acid compounds for liver disease
AU2012259422A8 (en) Solid forms of a pharmaceutically active substance
EA201300146A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ МОДУЛЯТОРА c-МЕТ
EA201591527A1 (ru) Новые производные пиридина
GEP20166432B (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
MY183312A (en) Pharmaceutical formulation
GEP20156263B (en) Substituted azoles, anti-viral active ingredient, pharmaceutical composition, method for production and usage thereof
EA201270741A1 (ru) Пероральные композиции и липофильные соли метилналтрексона
GEP20156318B (en) Heteroaryl derivatives as alpha7 nachr modulators
MX352245B (es) Formulacion farmaceutica que comprende una droga biofarmaceutica.
GEP201706621B (en) Benzamides
MA33948B1 (fr) Dérivés d'acide 3-hétéroaroylamino-propionique substitues par oxygène et leur utilisation en tant qu'agents pharmaceutiques.
UY34314A (es) Derivados de anilina, su preparación y su aplicación terapéutica.
MX340147B (es) Composiciones farmacéuticas y nutracéuticas del ácido abscísico.
UA110128C2 (uk) Індолкарбоксаміди та бензімідазолкарбоксаміди як інсектициди та акарициди
EA201200616A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
EA201300034A1 (ru) Фармацевтические композиции, содержащие иматиниб или его фармацевтически приемлемую соль, и способы их получения

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/06/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME MEDIDA CAUTELAR DE 07/04/2021 - ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/06/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF